Glycan Display Platform

Glycan Display Platform

CD BioGlyco is at the forefront of glycobiology, offering a cutting-edge glycan display platform and comprehensive services that empower our clients to explore, analyze, and manipulate glycans with precision and flexibility for applications such as drug development.

Comprehensive and Custom Glycan Display Service at CD BioGlyco

Our glycan display platform stands out for its versatility, offering traditional glycan display, cell-based glycan display, neoglycolipid (NGL) display, liquid glycan display (LiGA), glyco-phage display, and de novo glycan display methodologies. Our service advantages lie in providing tailored solutions for glycobiology research, spanning drug discovery, biosensor development, and glycan-protein interaction studies. With a commitment to excellence, we collaborate closely with clients, offering a platform for advancing their specific research goals.

Traditional Glycan Display Array

At CD BioGlyco, our traditional glycan display array services encompass Natural oligosaccharide library construction, Chemical and Enzymatic synthesis-based oligosaccharide library construction, Modular synthesis-based oligosaccharide library construction, oligosaccharide library Immobilization, Glycan Microarray Assay, and more. These services provide researchers with a comprehensive toolkit to explore diverse glycan structures and interactions, ultimately advancing glycobiology research.

Fig.1 The standard process of the traditional glycan display array. (CD BioGlyco)Fig.1 The standard process of the traditional glycan display array. (CD BioGlyco)

Our glycan microarray assay includes but is not limited

Cell-based Glycan Display Array

CD BioGlyco provides the cell-based glycan display array, leveraging cutting-edge service technologies to delve into the intricate interplay of glycans within cellular environments. Our advanced offerings encompass precise Glyco-engineered Cell Construction, and the development of cell-based O-Glycan, N-Glycan, GAG, and Glycoprotein arrays.

Through a streamlined service process, we apply sophisticated techniques in customized cell engineering design, ensuring accurate glycan presentation. Meticulous construction is followed by rigorous quality control, validating glycan structures and array functionality. This technologically driven approach empowers researchers to unravel the complexities of glycans at the cellular level, propelling glycobiology research to new frontiers. Below are our custom cell construction services.

Neoglycolipid (NGL) Display Array

CD BioGlyco presents the NGL display array, a specialized service catering to the exploration of glycans in unique lipid contexts. This offering enables researchers to study glycan-lipid interactions and their implications across diverse applications. Our service encompasses the creation of tailored NGL display arrays, providing a platform for in-depth investigations into glycan-lipid interplay. Through advanced methodologies, we ensure precise and reliable presentation of neoglycolipids, empowering researchers to unlock new insights in glycobiology. With CD BioGlyco's expertise, the NGL display array becomes a valuable tool for unraveling the intricate roles of glycans in lipid-based environments.

Fig.2 Schematic representation of the NGL-based microarray system. (Palma, et al., 2014)Fig.2 Schematic representation of the NGL-based microarray system. (Palma, et al., 2014)

Liquid Glycan Display Array (LiGA)

CD BioGlyco introduces the LiGA, a cutting-edge service designed to unravel the complexities of glycans in liquid environments. This innovative offering provides researchers with a versatile platform for studying glycan interactions and functions in a fluidic context. Our LiGA service involves the construction of dynamic glycan arrays, allowing for high-throughput screening and in-depth analysis. With precision and adaptability, CD BioGlyco empowers researchers to explore liquid-phase glycan dynamics, advancing the understanding of glycobiology.

Here are the LiGA services you can find at CD BioGlyco

Fig.3 LiGAs identify the glycoconjugates with optimal avidity necessary for binding to lectins. (Sojitra, et al., 2021)Fig.3 LiGAs identify the glycoconjugates with optimal avidity necessary for binding to lectins. (Sojitra, et al., 2021)

Glycophage Display

CD BioGlyco spearheads glycophage display technology with a range of specialized services. Our offerings include N-linked and O-linked glycoprotein glycophage display system construction, glycophage display-based Glycosylase Genetic Analysis, Glycoarray, Antibody Development, Epitope Mapping, and Biomarker Development. Through advanced service technologies, we meticulously construct tailored glycophage display systems, enabling high-precision glycan analysis, array development, antibody generation, epitope mapping, and biomarker discovery.

De Novo Glycan Display

De novo glycan display facilitates the elucidation of glycan structures, including the sequence and linkage information of monosaccharides within complex glycans. This is crucial for understanding the biological functions of glycans in various physiological and pathological processes.

Here are the de novo glycan display services you can find at CD BioGlyco.


Technology: Sanger sequencing and deep sequencing, MALDI analysis, Protein-binding experiments, Cell-based assays, Animal experiments, Statistical analysis

Journal: Nature Chemical Biology

IF: 14.8

Published: 2021

Results: In constructing LiGA building blocks, researchers selected the scalable M13 platform for its stability and compatibility with various cloning methods and conjugation strategies. Despite the non-glycosylated nature of the M13 virion, we chemically conjugated desired glycans to a subset of the major coat protein pVIII, creating a multivalent display of ~200–1,500 glycans on the virion. Leveraging a silent barcode near the pIII cloning site enabled the assembly of a glycan library with distinct DNA-encoded barcodes. Using synthetic glycans with an alkyl-azido linker, SPAAC ligation allowed efficient conjugation, providing semi-quantitative estimates of glycan densities. This robust construction methodology facilitates diverse applications in glycobiology research.

Fig.4 Synthesis and characterization of LiGA components. (Sojitra, et al., 2021)Fig.4 Synthesis and characterization of LiGA components. (Sojitra, et al., 2021)


  • Facilitating high-throughput screening to identify glycans with specific interactions, aiding in the discovery of potential therapeutic candidates.
  • Contributing to the creation of innovative biosensors for real-time monitoring of glycan interactions, enabling sensitive and specific detection methods.
  • Providing a platform for in-depth studies on glycan-protein interactions, unraveling the complexities of biological processes and potential therapeutic targets.
  • Allowing the assembly of glycan libraries with distinct DNA-encoded barcodes, providing researchers with a comprehensive toolkit for studying a variety of glycan structures.


  • Advanced glycan display platform

Access to a cutting-edge glycan display platform that supports diverse methodologies, such as traditional glycan display, cell-based glycan display, NGL display, LiGA, glycophage display, and de novo glycan display.

  • Customized solutions

Tailored services that allow researchers to customize experiments based on specific project requirements, providing flexibility in addressing unique research objectives.

  • Comprehensive glycan library creation

Expertise in creating glycan libraries with distinct DNA-encoded barcodes, enabling researchers to explore a wide range of glycan structures for various applications.

At CD BioGlyco, our advanced glycan display platform and suite of services empower clients across diverse applications. From facilitating high-throughput screening for drug discovery to enabling precise glycan engineering for therapeutic proteins, our platform serves as a versatile tool. Additionally, it contributes to the development of innovative biosensors, aids in glycan-protein interaction studies, and offers tailored solutions for a wide range of research needs, further solidifying its pivotal role in advancing glycobiology research and applications. Please do not hesitate to contact us for more details if you are interested in our services and advanced platform.


  1. Palma, A.S.; et al. The neoglycolipid (NGL)-based oligosaccharide microarray system poised to decipher the meta-glycome. Current opinion in chemical biology. 2014,18: 87-94.
  2. Sojitra, M.; et al. Genetically encoded multivalent liquid glycan array displayed on M13 bacteriophage. Nature Chemical Biology. 2021, 17(7): 806-816.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.